Industry Partner News: Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD

Summit logo.png

Summit Therapeutics announced additional positive data from PhaseOut DMD, showing a significant reduction in muscle inflammation after 24 weeks of ezutromid dosing. The findings in this 24-week interim data are consistent with the expected activity of ezutromid to stabilize muscle fiber membranes and thereby reduce muscle fiber damage and inflammation. A statistically significant and meaningful reduction in muscle fiber damage was observed in previously reported 24-week findings from patient biopsies in PhaseOut DMD, and now we’re reporting a decrease in muscle inflammation.

Learn more at www.summitplc.com.